The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Many of those receptors transmit anti-apoptotic, proliferative and differentiation signals, and their expression and functions are critical for the formation of blood lineages. Several cancers, including blood malignancies, have been associated with constitutive activation of members of the STAT family, which normally require JAK-mediated tyrosine phosphorylation for transcriptional activation. More recently, human myeloproliferative neoplasms were discovered to be associated with a unique acquired somatic mutation in JAK2 (JAK2 V617F), rare exon 12 JAK2 mutations, or thrombopoietin receptor mutations that constitutively activate wild-type JAK2. Prompted by these observations, many studies have explored the possibility that JAKs, cytokine receptors, or other components of the JAK/STAT pathway are mutated or upregulated in several hematological malignancies. This has been observed in certain pediatric acute lymphoblastic leukemias and adult T-cell lymphoblastic leukemias, and overexpression of JAK2 seems to be important in Hodgkin lymphoma. Here we discuss the nature and respective contribution of mutations dysregulating the JAK/STAT pathway in hematological malignancies and present examples in which such mutations drive the disease, contribute to the phenotype, or provide a survival and proliferative advantage. JAK inhibitors are making their way into the therapeutic arsenal (for example, in myelofibrosis), and we discuss the possibility that other hematological diseases might benefit from treatment with these inhibitors in combination with other agents.
INTRODUCTION
The understanding of the mechanisms by which an extracellular signal can modify the biology of a cell by activating transcription has been greatly advanced by investigating cytokine receptor signaling. Particularly, studies of transcriptional induction by the cytokines interferon a, b and g via their cognate receptors have facilitated defining the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. 1, 2 This pathway begins by the binding of a cytokine to its cognate receptor, which basally is completely inactive. Cytokine binding induces a conformational change that either reorients a preformed dimer [3] [4] [5] [6] or induces receptor dimerization/oligomerization. 7 As a consequence, JAKs, prebound to the receptors' cytoplasmic region, become activated, leading to cross-phosphorylation and receptor tyrosine phosphorylation, thus creating binding sites for cytoplasmic proteins such as the STAT proteins, which become substrates for JAKs. 8 Phosphorylation leads to STAT homodimerization and translocation to and retention in the nucleus, where they act as transcription factors (Figure 1) . This pathway has a central role in the signaling of cytokines by regulating cell proliferation, survival, differentiation and immune response. Consequently, it has become clear that the JAK/STAT pathway also has an important role in oncogenesis. 9, 10 In addition to STAT activation, JAK signaling activates other signaling pathways such as mitogen-activated protein kinase (MAPK), phosphatidylinositol-3'-kinase (PI3K) and AKT/mammalian target of rapamycin (mTOR) (Figure 1 ). Additionally, STAT proteins can be activated by other kinases, such as SRC family kinases. 10 Activation of STAT proteins, especially STAT5 and STAT3, is important in the pathogenesis of lymphoid and myeloid malignancies. [11] [12] [13] [14] Until recently, few genetic alterations had been found in this pathway, with the exception of mutations or silencing of negative regulators and the presence of rare oncogenic JAK2 fusion proteins. 15 The recent discovery of a recurrent activating somatic mutation in JAK2 in more than 50% of classical myeloproliferative neoplasms (MPNs) has emphasized the role of JAKs in oncogenesis. [16] [17] [18] [19] Following this discovery, genetic alterations in JAK2, JAK1 and JAK3 were discovered in hematological malignancies [20] [21] [22] [23] as well as in other JAK regulators, such as cytokine receptors (myeloproliferative leukemia protein (MPL)/ thrombopoietin receptor (TPOR), cytokine receptor-like factor 2 (CRLF2), interleukin-7 receptor a (IL-7 Ra)) [24] [25] [26] [27] and LNK. 28 In this review, we focus on the role of the JAK/STAT pathway in hematological malignancies, particularly those with alterations in genes directly involved in this pathway and the role of JAKs as potential therapeutic targets. signaling by more than 30 cytokine receptors that belong to the cytokine receptor superfamily. 29 A principal feature of cytokine receptors is the preassociation with JAK proteins, which promotes traffic and stability [30] [31] [32] [33] and stringent cytokine dependency for signaling. Receptors interact with high affinity with cytokines, and 50% biologic activity can be obtained at o10% receptor occupancy rates. 34 Myeloid JAK/STAT signaling Upon cytokine binding, JAK activation opens the path to downstream signaling via particular STAT proteins, MAPK, and PI3K/AKT pathways, in proportions that depend on each receptor. 35 The three type-I homodimeric proteins, erythropoietin receptor (EPOR), MPL/TPOR, and granulocyte colonystimulating factor receptor (G-CSFR) employ JAK2; [36] [37] [38] however, MPL/TPOR can also activate TYK2, with low signaling output, 33, 37 and G-CSFR employs JAK1. 39 EPOR activates mainly STAT5, whereas MPL/TPOR and G-CSFR strongly activate STAT3. MPL/ TPOR also induces STAT1 activation. 40 MPL/TPOR and G-CSFR strongly activate the MAPK extracellular-regulated kinase 1/2 (ERK1/2) pathway, whereas EPOR activates this pathway to a lesser degree. 38, 41, 42 Disrupting the physiological ratio between STAT5 and STAT3 can lead to leukemia, as is seen with G-CSFR truncations. 43 In addition to the homodimeric receptors, GM-CSF and IL-3 utilize heterodimeric receptors that contain the common b chain, which signals also via JAK2. 29 Although IL-6 family members signal mainly via JAK1, gp130 and other chains can also activate JAK2. 29 Lymphoid JAK/STAT signaling The JAK/STAT pathway also regulates formation of lymphoid cells. Cytokines that bind to receptors containing the common g chain, such as IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21, are crucial for formation and function of T, natural killer and B cells. 44 These receptors activate JAK1 via cytokine-binding chains and JAK3 via the common g chain. 45 Kinase-dead versions of JAK3, or an inhibitor that specifically blocks the catalytic activity of JAK3, but not of JAK1, still allow residual signaling via these receptors, suggesting that a major role of JAK3 is that of a scaffold and partner of JAK1. 46 These results suggest that highly specific JAK3 inhibitors may not prove as useful as once predicted in blocking autoimmune or oncogenic signaling via JAK3-associated cytokine receptors. Most receptor signaling via JAK1-JAK3 activate STAT3 and STAT5. 47 Termination of JAK/STAT signaling Physiologically, signaling by cytokine receptors is transient. The termination of the signal is due to (1) internalization and degradation of the receptors by the lysosome and proteasome pathways, which require ubiquitination of intracellular domain lysines. 33, [48] [49] [50] [51] JAK activation is required for degradation of internalized receptors, as was demonstrated for TYK2 and interferon a, b, and o receptor 1; 52 (2) phosphatase recruitment Figure 1 . Cytokine receptors exist on the cell surface in an inactive state bound to JAKs via their cytosolic domains. The binding of a specific ligand induces a conformational change in the preformed dimer, leading to tyrosine phosphorylation and cross-activation of JAKs, which phosphorylate intracellular receptor tyrosine residues (Y-P). In turn, the phosphorylated residues attract signaling adaptor proteins that recognize specific tyrosine phosphorylated sequences. Various adaptor proteins become substrates of JAKs, triggering signaling cascades. Cytokine receptors are linked to the STAT, Ras-MAPK, and phosphatidylinositol-3'-kinase (PI3K)-AKT pathways, which converge at the nucleus and regulate gene expression. Left, unliganded inactive cytokine receptor; middle, ligand-activated receptor, which is transient and induces anti-apoptotic, proliferative, and differentiation signals. Right, unliganded receptor that is constitutively active because of the attachment of JAK2 V617F, a constitutively active JAK, and is therefore recapitulating the cytokine-induced pathway, although in a persistent manner. Novel signaling molecules (X, Y and Z) become substrates of activated JAK, initiating novel interactions (X, Y and Z interactors) that change gene expression and/or induce novel epigenetic events.
to the receptor, thereby dephosphorylating JAKs; 53 (3) recruitment of negative regulators that are transcriptionally induced by cytokines, such as cytokine-induced SH2-containing protein 1 and suppressors of cytokine signaling 1 to 7 (SOCS1-7) proteins; 43, [54] [55] [56] [57] [58] and (4) interaction of STAT proteins with protein inhibitors of STATs (PIAS) family members, which induce small ubiquitin-related modifiers-(SUMO)-ylation of several transcription factors and form signaling platforms localized to subnuclear regions. 59 PIAS family members can repress transcriptional activity of transcription factors, such as the CCAAT/enhancer-binding protein delta (C/EBPd) in an independent manner from the SUMOylation activity. 60 A substantial body of evidence has revealed that constitutively active cytokine receptors, obtained by in vitro mutagenesis, such as those that are artificially dimerized by disulfide bonds in active conformations, that is, EPOR R129C or MPL/TPOR S368C 61, 62 lead to permanent signaling. Thus, constitutively active STAT proteins in the nucleus overcome negative regulatory mechanisms, eventually leading to oncogenesis. 63 
GENETIC ALTERATION OF JAKS IN HEMATOLOGICAL MALIGNANCIES
JAK2 fusion proteins Translocation ETS leukemia (TEL)-JAK2 was the first JAK2 fusion protein to be discovered in a malignancy of a patient with T-cell childhood acute lymphocytic leukemia (ALL). 15 TEL, also called ETS variant 6, has been found to be involved in other translocations associated with leukemias. The TEL-JAK2 protein results from a fusion between the oligomerization domain of TEL and the kinase domain of JAK2 and exhibits constitutive tyrosine kinase activity by promoting oligomerization of JAK2. 15 The TEL-JAK2 fusion is associated with rare B-cell or T-cell leukemia as well as atypical chronic myeloid leukemia. 64 The TEL-JAK2 fusion protein constitutively activates STAT1 and STAT5 and the PI3K, RAS/ERK, p38 and NF-kB signaling pathways. 65 In transplantation assays, TEL-JAK2 induces a fatal lymphomyeloproliferative disease, with development that depends on STAT5. 66 When human cord blood CD34
þ cells transduced with a vector encoding TEL-JAK2 are transplanted into immunodeficient mice, the mice develop myelofibrosis (MF), a myeloproliferative disorder. 67 Additionally, the pericentriolar material 1 (PCM1)-JAK2 fusion protein 68 was identified in several cases of chronic and acute leukemia 69 and T-cell lymphoma. 70 PCM1 encodes a centrosomal protein, the human autoantigen PCM1, predicted to contain a number of coiled-coil domains.
Other oncogenic JAK2 fusion proteins have been described with partner proteins such as breakpoint cluster region (BCR), singlestranded DNA-binding protein 2, calmodulin-binding protein 3 striatin and paired box 5 (PAX5) in MPNs and acute leukemia. [71] [72] [73] In pediatric ALL, PAX5, a master regulator of B-cell development, is rearranged in 2.5% of B-cell precursors, including the JAK2 fusion protein PAX5-JAK2, which has been implicated in tumorigenesis. 73 More recently, a fusion between SEC31A and JAK2 created by a t(4;9)(q21;p24) was reported in B3% of patients with Hodgkin lymphoma. 74 SEC31A is involved in vesicular transport and has been shown to be present in another fusion with anaplastic lymphoma receptor tyrosine kinase in some forms of large B-cell lymphoma. The SEC31A-JAK2 fusion protein leads to constitutive JAK2 activity that can be blocked by JAK2 inhibitors. Overall, in all cases, the expression of the fusion protein containing the JAK kinase domain is driven by the promoter of the fusion partner, which induces oligomerization and activation of the JAK kinase.
In addition, the JAK/STAT pathway may have an important role in the pathogenesis of Hodgkin lymphoma as the JAK2 locus is amplified in B30% of cases, 74 supporting the notion that JAK overexpression can be oncogenic. 75 In Hodgkin lymphoma, survival has been correlated with expression of a microRNA, miR-135a, which targets JAK2. 76 Furthermore, loss-of-function SOCS1 mutations and deletions in nonreceptor type protein tyrosine phosphatase 2 (PTPN2) have been described, leading to activation of JAK/STAT signaling. 77, 78 JAK mutations More recently, JAK mutations have been found in hematological malignancies. The classical non-BCR-ABL MPNs, polycythemia vera (PV), essential thrombocythemia (ET), and primary MF (PMF), are chronic clonal disorders that arise from the hematopoietic stem cells, clinically characterized by the production of an excess of mature blood cells and biologically by a hypersensitivity or independence to cytokines such as erythropoietin (EPO). 79 Initially, JAK2 was an obvious candidate as a 9p loss of heterozygosity in a region that includes JAK2 had been described in 30% of cases of PV. 80 In 2005, an acquired mutation in exon 14 of JAK2, a guanineto-thymidine substitution that results in a substitution of valine to phenylalanine at codon 617 (JAK2 V617F), was found in more than 90% of patients with PV and 50% of those with ET and PMF. [16] [17] [18] [19] JAK2 V617F is a gain-of-function mutation located in the pseudokinase domain of JAK2 (JAK homology 2 [JH2]) (Figure 2 ), which negatively regulates the kinase domain (JH1), possibly via ATP binding and autophosphorylation 81 of sites known as Figure 2 . Domain structure of JAK2. JAK2 contains a tyrosine kinase domain (JAK homology 1 (JH1)), a pseudokinase domain (JH2), SH2-like domain, and a domain that resembles protein 4.1, ezrin, radixin and moesin (FERM). The latter domain is responsible for attachment to the cytosolic domains of cytokine receptors. The pseudokinase domain, JH2, functionally prevents the activation of the kinase domain, JH1 (curved arrow on the top). In contrast, mutations in the pseudokinase domain (red) lead to activation (arrow on the bottom) of JH1. The V617F mutation has been identified primarily in MPNs, whereas the R683 mutation (located in the hinge between the N-and C-lobes of JH2) has been uniquely identified in pediatric leukemia.
negative regulatory sites (S523, Y570). [82] [83] [84] In contrast to JAK2 fusion proteins, which signal autonomously, JAK2 V617F requires activation of cytokine receptors for oncogenic signaling, especially dimeric receptors such as G-CSFR, EPOR and MPL/TPOR. 85 However, JAK2 V617F can also induce the canonical pathways of these receptors in the absence of cytokines (Figures 1 and 2 ). This includes the activation of STATs, PI3K and MAPK/ERK pathways, respectively. 17, 19, 86 The choice of activated STATs may largely depend of the receptor type, for example, essentially STAT5 for EPO-R and STAT3, STAT5 and STAT1 for MPL. When introduced in cytokine-dependent cell lines, JAK2 V617F induced cytokine independence and hypersensitivity, 17 including to insulin-like growth factor 1. 87 In different murine models, JAK2 V617F induced a myeloproliferative disorder, often phenocopying PV that progresses to MF, and an ET-like disorder. [88] [89] [90] [91] [92] [93] [94] It has been suggested that both in humans and mice, the phenotype of the disease depends on the intensity of the signaling, which is related to the number of JAK2 V617F copies. 89 Supporting this hypothesis, most patients with PV have a homozygous mutation through a mitotic recombination leading to the 9p loss of heterozygosity, whereas the majority of patients with ET have a heterozygous mutation. 95, 96 The phenotype of the disease induced by JAK2 V617F might also depend on the activation of specific downstream signals because PV, ET and PMF are associated with strong STAT5, STAT1 and STAT3 activation, respectively. 86, 97 In in vitro experiments, the EPO independence induced by JAK2 V617F required both STAT5 and PI3K activation. 98, 99 Two recent studies established that STAT5A/B activation is crucial for development of JAK2 V617F-positive MPNs in mouse models 100, 101 using an inducible double STAT5A/B knockout strategy, 102, 103 suggesting that inhibitors of STAT5 could be useful in MPNs. Residual STAT5 activation after incomplete JAK2 inhibition might explain the apparent inability of JAK2 inhibitors to reduce the JAK2 V617F allele burden, although more data are required to resolve this issue. [104] [105] [106] There is also increasing evidence that other clonal mutations in epigenetic regulators such as TET2 and ASXL1 or in the splicing machinery are present in a fraction of JAK2 V617F-positive MPNs and other myeloid malignancies. [107] [108] [109] This is especially true for PMF, in which such mutations are present in more than 50% of patients. Whether JAK2 V617F is the initiating event in these MPNs is controversial and is presently under investigation, but JAK2 V617F seems to drive the phenotype of the disease. This was further confirmed in sideroblastic anemia with thrombocytosis, a form of myelodysplastic syndromes (MDS), in which the sideroblastic anemia seems related to a splicing factor 3b subunit 1 mutation 110 and the thrombocytosis to JAK2 V617F.
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JAK2 V617F is not only a preactivated molecule but has also acquired additional properties: (1) Saturation mutagenesis at position V617 showed that Trp, Met, Leu and Ile also induced constitutive activation of JAK2, with JAK2 V617W being the strongest and Ile the weakest. 121 Very rarely, patients with MF have been reported as carrying the JAK2 V617I mutation. 122 For example, a JAK2 V617I germline mutation was recently described in a family with hereditary autosomal dominant thrombocytosis. 123 Interestingly, this weaker mutation only induced thrombocytosis, possibly fitting the model that low JAK2 activation will induce ET, whereas stronger JAK2 activation will induce PV and PMF. 123 JAK2 exon 12 mutations in PV Activating JAK2 mutations are observed in more than 97% of patients with PV. Different somatic gain-of-function mutations in exon 12 of JAK2 have been found in a fraction of patients with JAK2 V617F-negative PV. 124 These genetic alterations are usually complex but most frequently affect a single residue (K539). Although not located in the pseudokinase domain, K539 mutants may lead to the same change in JH2 domain structure as V617F. In contrast to JAK2 V617F, exon 12 mutants are not associated with ET and PMF. 125 The majority of patients with PV with JAK2 exon 12 mutations exhibit clinical features of an idiopathic erythrocytosis, but these patients also progress to secondary MF. 126 JAK MUTATIONS AND LEUKEMIA JAK2 A deletion in the pseudokinase domain of JAK2 called JAK2DIREED including R683 was initially discovered in a patients with Down syndrome (DS) and B-cell ALL (B-ALL). 127 Expression of JAK2DIREED in Ba/F3 cells induced constitutive activation of the JAK/STAT pathway and growth factor-independent cell proliferation. 127 Subsequently, JAK2 mutations located in the pseudokinase domain, especially at R683, but also in the kinase domain, were found in B20% of patients with DS and B-ALL. 128, 129 These JAK2 mutants are associated with CRLF2 rearrangements, leading to overexpression of this receptor. 25 CRLF2, located on chromosome X, encodes a lymphoid cytokine receptor that heterodimerizes with IL-7 Ra to form the receptor for thymic stromal lymphopoietin. CRLF2 overexpression favors the transforming activity of JAK2 R683 mutants in Ba/F3 cells.
Interestingly, the DS ALL with JAK mutations had similar gene expression signatures with BCR-ABL B-ALL, with frequent deletions in IKAROS family zinc finger 1 and cyclin-dependent kinase 2 inhibitor A/B. 130 This defines a subgroup of activated tyrosine kinase signature ALL that usually has a poor prognosis, which may also include patients with genomic rearrangements in tyrosine kinases other than JAK and ABL, and therefore, may benefit from new therapeutic approaches.
Importantly, JAK mutations and overexpression of CRLF2 have also been detected in other cases of pediatric B-ALL (without DS), with a frequency between 4% and 7%. 20, 23, 25 In nearly all cases, JAK mutations are associated with an overexpression of CRLF2. However, overexpression of CRLF2 is much more frequent than JAK mutations and can be associated with other mutations such as IL-7 R. 131 An activation mutation in JAK2 (T875N) has been described in a cell line derived from acute megakaryoblastic leukemia (AMKL), CHRF-288-1, which has not yet been found in primary samples from patients with AMKL.
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JAK1
Somatic mutations in JAK1 have been found in 10 to 20% of cases of T-cell ALL (T-ALL) 20, 133, 134 and less frequently in B-ALL. Mutations are located in the protein 4.1, ezrin, radixin and moesin (FERM) and the pseudokinase domain as the V658F mutant, 20, 133, 134 equivalent to JAK2 V617F and shown previously to be active. 87 They also require signaling receptors such as IL-7R, IL-9 Ra, or IL-2 Rb for constitutive activation. 135 Some JAK1 mutations are associated with deletions in negative regulators such as PTPN2 136 or CD45 (protein tyrosine phosphatase receptor C). 137 As in B-ALL, the JAK/STAT pathway may have an important role in the pathogenesis of T-ALL as IL-7 R-and JAK3-activating mutations as well as loss-of-function mutations in SH2B3 (LNK) have been found in 15% of the cases. 27, 133 Rare (1%-2%) JAK1 mutations have also been described in acute myeloid leukemia (AML). 21, 22 JAK3 and TYK2 JAK3 mutations have been detected in rare cases of adult T-cell leukemia/lymphoma, cutaneous T-cell lymphoma, 138 and more recently in T-ALL. 133 Interestingly, three gain-of-function (L156P, E183G, R172Q) mutations were found in the FERM homology domain of JAK3 in adult T-cell leukemia/lymphoma. 139 Moreover, JAK3 mutations (JAK3 A572V, A573V, P132A) have been described in AMKL. 132, 140, 141 These results suggest either that a gc-coupled receptor expressed in the megakaryocyte lineage might be involved in supporting signaling by this JAK3 mutant or that upon mutation, JAK3 acquires the ability to bind another receptor.
Taken together, these data indicate that JAK mutants require cytokine receptor dimers/oligomers for constitutive signaling, and it remains to be established whether mutant JAKs exert the same specificity as wild-type JAKs for cognate receptors.
TYK2 mutations seem to be very rare in hematological malignancies. Several nonsynonymous germline sequence variants have been associated with AML but do not seem to be consistent in affecting kinase activity. 21 They seem to correspond to polymorphisms linked to a predisposition to leukemia, leading to either normal or decreased signaling function. 21 A germline TYK2 P1104A variation was previously linked to tumor tissue and was predicted to exhibit impaired function. 142 Similarly, it has been shown that the 46/1 haplotype related to the JAK2 locus increases the probability to develop JAK2 V617F MPN 3-to 5-fold.
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GENETIC ALTERATIONS IN DOWNSTREAM COMPONENTS OF THE JAK/STAT PATHWAY STAT proteins
Although constitutive STAT activation is very frequent in hematological malignancies, very few mutations in STAT genes have been yet described. Mutations in the STAT6 DNA-binding domain have been found in primary mediastinal B-cell lymphoma (36%), which may lead to a loss-of-function. 146 However, the oncogenic properties of these mutants remain to be determined. A possible hypothesis may be related to a cross-talk between STAT1 and STAT6. 147 Thus, these loss-of-function mutations may inhibit negative regulation mediated by STAT1. Like for some solid tumors, 148 recurrent activating mutations of STAT3 have been found in large granular lymphocytic leukemia. 149 No recurrent mutations in STAT1, STAT3 and STAT5 have yet been found in the other hematological malignancies.
Cytokine receptors Gain-of-function mutations in cytokine receptors, which induce constitutive JAK activation, have been described in patients with MPNs, ALL, and very rarely in patients with AML. In addition, activating mutations in tyrosine kinase receptors (RTKs) such as FLT3 or KIT may activate STAT proteins independent of JAK activation.
MPL/TPOR and MPN Several activating mutations of MPL/TPOR have been found with a frequency of B5% and up to 15% in patients with ET and PMF. 24 Most involve W515 in exon 10, resulting in its substitution to leucine, lysine, asparagine or alanine 24, [150] [151] [152] [153] (Figure 3 ). Tryptophan-515 is located in an amphipathic motif (K/RWQFP) in the cytoplasmic region just after the transmembrane domain and prevents spontaneous activation of the receptor. 154 These MPL mutants induce a constitutive activation of JAK2 that is responsible for myeloproliferative disorders in animal models. 24 In addition to JAK2 activation, MPL W515 mutants require tyrosine 626 in the cytosolic domain to induce oncogenic signaling, 153 which links the receptor to the STAT3 and MAPK-ERK1/2 pathways. Altogether, this supports the contention that classical BCR-ABL-negative MPNs are related to an abnormal JAK2 activation. In addition, the MPL S505N mutation, initially described in familial thrombocytosis, 155 was also found in rare sporadic MPNs 151, 156 ( Figure 3 ). Furthermore, rare MPL mutations (three cases of MPL W515L and one case with a new mutation, T487A) have been described in primary or secondary AMKL. 132, 157 IL-7R and CRLF2 in ALL In B-and T-ALL, somatic gain-of-function IL-7R exon 6 mutations have been found with a frequency of B9% in patients with T-ALL. 27, 158 In most cases, these mutations introduce an unpaired cysteine in the extracellular juxtamembrane-transmembrane region and promote dimerization of the receptor, inducing constitutive JAK1 activation. In B-ALL, these mutations are associated with an overexpression of CRLF2 (see above) forming a functional, spontaneously activated receptor for thymic stromal lymphopoietin. 158 Interestingly, mutations in CRLF2 have also Figure 3 . The MPL/TPOR contains a unique RWQFP cytosolic juxtamembrane domain motif. W515 in the motif has been found to be mutated in 5% to 10% of patients with essential ET and primary myelofibrosis (PMF) that do not harbor JAK2 V617F. These W515 mutations lead to cytokine-independent activation of the receptor, which then signals constitutively via JAK2. Activating TPOR transmembrane S505N mutations have been identified in familial ET. These receptors form active dimers in the absence of the TPO ligand and signal constitutively via JAK2. In rare human megakaryoblastic leukemia cell lines, an extracellular juxtamembrane T487A-activating mutation has been identified.
been described (F232C) that result in the addition of a cysteine in the juxtamembranous domain of the cytokine receptor.
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G-CSFR and AML Activating mutations of G-CSFR (colony-stimulating factor 3 receptor (CSF3R)) are rare in AML but have been described in a few cases 160 and, furthermore, may be secondary mutations occurring during disease progression. 160 The mutation reported in these cases (Thr617Asn) leads to JAK2 activation and can be found in familial neutrophilia. 161 Acquired mutations of G-CSFR have been described in children with severe congenital neutropenia undergoing granulopoiesis-stimulating factor treatment. 162 These mutations lead to a truncation in the G-CSFR cytoplasmic domain, impairing its ligand-induced internalization and leading to prolonged STAT5 activation and decreased SOCS3 binding that can precede the development of MDS/leukemia from a few months to several years. During disease progression, other mutations of G-CSFR located in the extracellular domain can appear and may lead to cytokine independence. 163 MOLECULAR ALTERATION IN RTKs AND THE JAK/STAT PATHWAY Acquired fusion proteins or gain-of-function mutations in several RTKs such as FLT3, KIT, platelet-derived growth factor receptor, fibroblast growth factor receptor, and anaplastic lymphoma receptor tyrosine kinase have been described in different hematological malignancies including leukemia, mastocytosis and MPNs, 164 which are associated with strong activation of STAT proteins such as STAT1, STAT3 and STAT5. [165] [166] [167] There is also convincing evidence that STAT activation, especially that of STAT5, is essential in the transformation mediated by most of these mutants, especially for FLT3 ITD and KIT D816V. 168, 169 The wild-type receptor either weakly or does not activate the STAT proteins, and thus, mutations induce an important switch in initiating STAT activation. The mechanism of this activation remains unclear, but there is evidence that the location of the activating receptor in the endoplasmic reticulum and signaling from the cytoplasmic compartment, along with resistance to ubiquitin-dependent degradation, may greatly contribute to activation. 168, 170 There is also evidence that the kinase domain of the receptor can directly phosphorylate different STAT proteins and that indirect phosphorylation can occur through SRC family kinases or the JAKs. Interestingly, it has been shown that in the mast cell line HMC-1.1 (KIT V560G) and 1.2 (KIT V560G and D816V), JAK2 was found to be constitutively activated and TG101348, a JAK2 inhibitor, inhibited JAK2 phosphorylation as well as STAT3 and STAT5. 171 Thus, the role of JAK in STAT activation depends on both the type of RTK mutation and on the cell type.
JAK/STAT NEGATIVE REGULATORS
As mentioned previously, the JAK/STAT pathway is negatively regulated by several types of proteins acting on the degradation of JAKs and STAT proteins (SOCS, PIAS), on JAKs or receptor phosphorylation (LNK, phosphatase), or on the degradation of the cytokine receptors (Casitas B-cell lymphoma (CBL)). Genes coding for most of these proteins can be considered tumor suppressor genes, and their inactivation (mutations, silencing) potentiates JAK/STAT signaling when mutations of JAK are present. In certain cases, they may be the main event in dysregulating the pathway. However, some of these molecules may also have the opposite effect. For example, some phosphatases, such as SHP2, are directly involved in positive signaling and are associated with gain-offunction mutations, which affect the RAS pathway more than the JAK/STAT pathway. Furthermore, SOCS overexpression can be observed in some malignancies, allowing for resistance to the antiproliferative effect of interferons. 172 LNK LNK, also called SH2B3, is a member of the SH2B family, which contains two other members 173 and has an important role in hematopoiesis by negatively regulating JAK2 activation through its SH2 domain. 174, 175 In murine models, the knockout of LNK leads to myeloproliferation associated with MF. 176 In humans, rare mutations in LNK have been found in patients with ET and PMF without other mutations in signaling molecules. 28 LNK mutations lead to loss of regulatory functions and consequently to increased JAK2/STAT signaling. LNK mutations have also been described during disease progression to AML. 177 In some cases, LNK mutations were associated with JAK2 V617F, suggesting, as in the murine models, 178 cooperation between these mutants. More recently, mutations in LNK have been found in chronic myelomonocytic leukemia, MPN/MDS, and in a case of T-ALL. 133 SOCS1, SOCS2 and SOCS3 SOCS proteins are also important negative regulators of JAK signaling through a classic feedback loop. 179 In addition, SOCS1 may be involved in the regulation of NF-kB signaling and p53 function. 180 Mutations in SOCS1 have been found in different pathologies, particularly in Hodgkin lymphoma, 77 in which they are associated with high levels of phospho-STAT5 and in primary mediastinal B-cell lymphoma (10% of the cases). 181 Mutations in SOCS are infrequent in MPNs, 182 possibly owing to the inability of SOCS3 to downregulate JAK2 V617F or exon 12 JAK2 mutant signaling. 112, 182 Hypermethylation of CpG islands in SOCS1 and SOCS3 associated with decreased expression has been described in several hematological malignancies, notably in lymphoid malignancies 183 and JAK2 V617F-positive and -negative MPNs. 184, 185 However, SOCS proteins can be overexpressed in T-cell lymphoma.
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PTPN1 and PTPN2 PTPN1 and PTPN2, also called protein tyrosine phosphatase 1B and T-cell protein tyrosine phosphatase, respectively, are capable of dephosphorylating JAKs. Deletion of the entire PTPN2 locus has been demonstrated in T-ALL (6% of the case), usually associated with activating mutations of JAK1. 136 A similar inactivation can be observed in cell lines derived from Hodgkin lymphoma but are rare in primary cells from patients. 78 Protein tyrosine phosphatase receptor C (CD45) CD45 is a transmembrane phosphatase, which regulates JAK2, particularly in response to IL-3 and EPO. 186, 187 Recently, loss-offunction mutations in CD45 were found in T-ALL primary cells and cell lines. 137 To this end, knockdown of CD45 in T-ALL increased JAK/STAT signaling and the signaling of JAK1 and IL-7Ra mutants.
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SHP1 (PTPN6) SHP1 mutations have not been described in hematopoietic malignancies. However, hypermethylation of its promoter has been described in multiple myeloma and lymphoma primary cells or cell lines associated with hyperphosphorylation of STAT3. 188, 189 SHP2 (PTPN11) Gain-of-function mutations in SHP2 are associated with hematological malignancies. Germline mutations are present in 50% of cases of Noonan syndrome, a syndrome characterized by multiple malformations including heart disease. This PTPN11 germline mutations as the somatic mutations may lead to juvenile myelomonocytic leukemia (35% of the case). In addition, somatic PTPN11 mutation may lead to other pediatric malignancies such as B-ALL, AML and MDS, but very rarely in adults. 190 There is evidence that dysregulation of the N-RAS-ERK pathway is critical in transformation by mutated SHP2, but dysregulation of the JAK2/STAT pathway seems also to be involved in this process.
CBL
The CBL proteins are multifunctional adapter proteins with ubiquitin ligase activity and major regulatory roles in RTK negative regulation. However, CBL proteins may have numerous targets other than RTK including JAK2, STAT5, and cytokine receptors such as MPL/TPOR, 191 and therefore, loss-of-function in CBL may lead to increased JAK/STAT signaling. CBL is mutated in a variety of myeloid malignancies, 192, 193 with the highest frequency in chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. CBL mutations have also been found in a low percentage of patients with PMF (6%). 194 
ACTIVATION OF THE JAK/STAT PATHWAY BY CYTOKINES AND SIGNALING BY CONSTITUTIVELY ACTIVE STAT PROTEINS
Autocrine or paracrine cytokine stimulation has a fundamental role in promoting solid tumor proliferation and in angiogenesis. This is less common in hematological malignancies, with the exception of some lymphoid malignancies, the best example being multiple myeloma. The interaction of myeloma cells with bone marrow induces an increased secretion of cytokines from both cell types. [195] [196] [197] Among them, IL-6 induces the activation of JAK2 and STAT3, critical for proliferation and survival. However, this STAT3 phosphorylation may also depend on mechanisms other than JAK2 activation. Several JAK2 inhibitors have been investigated for their effect on the growth and survival of multiple myeloma cell lines and primary plasma cells, and all inhibited cell proliferation and increased apoptosis. [198] [199] [200] In addition, ruxolitinib, a potent JAK2 inhibitor, enhanced the anti-tumor activity of chemotherapeutic agents in xenografts, offering promising preclinical results. 198 A common signaling event in many hematological malignancies is represented by constitutive activation of STAT3 and STAT5, which is translated by the persistent presence of phosphorylated STAT proteins on chromatin. [11] [12] [13] [14] With the exception of genetic alterations in cytokine receptors or in JAKs, the kinase responsible for phosphorylating STAT proteins remains controversial.
In chronic myeloid leukemia, STAT5 activation also participates in the development of MPNs. 100 In addition, resistance to imatinib may be mediated by an increased expression of STAT5. 201 Recent evidence has suggested that the development of MPNs is independent of JAK2 and that activation of STAT5 is directly mediated by BCR-ABL. 202 In AML, it has been suggested that SRC kinases promote STAT phosphorylation and survival. 203 Genes targeted by constitutively active STAT proteins are not always the same as those targeted by cytokine-induced STAT protein 204 ( Figure 4 ). For example, constitutively active STAT5B, but not cytokine-activated STAT5, induces the lipoma preferred partner gene, which is the host gene for miR-28, a microRNA that targets the 3'-untranslated region of MPL in MPNs. This miR is pathologically expressed in platelets from 30% of patients with MPN. treatment of MF-related splenomegaly or symptoms. Because none of the present compounds discriminate between wild-type and mutated JAK2, as a consequence of efficacy and their mechanism of action, JAK2 inhibitors may induce significant levels of anemia and thrombocytopenia, which is considered a toxic effect and can lead to treatment interruption. Additionally, it is unknown whether these inhibitors can target heterodimers such as JAK1/JAK2 and JAK2/TYK2, which may participate in G-CSF or TPO signaling.
Treatment of patients with MF with ruxolitinib has a modest impact in reducing allele burden and decreasing marrow fibrosis. Strikingly, and particularly in ruxolitinib treatment, two important positive effects of JAK2 inhibitors are substantial and rapid reduction of spleen size and decrease in constitutional symptoms. 105, 106, [209] [210] [211] [212] These effects are exerted both by JAK1/JAK2 inhibitors such as ruxolitinib and by other JAK2-specific inhibitors, as the SAR302503 (TG101348). For constitutional symptoms, inhibitors might prove beneficial in preventing the cytokine storm present in MF. 209 In contrast, the molecular basis for the spleen-reducing effects of JAK2 inhibitors remains unexplained. Clearly, the understanding of the players involved in these JAK2 effects will be important for future therapeutic improvement.
The development of mutant specific JAK2 inhibitors remains difficult because of the lack of a high-resolution crystal structure of both the entire JAK2 and the prevailing JAK2 V617F mutant. Recent structure and function studies suggest that targeting of the pseudokinase domain helix C-F595 and surrounding residues might uncouple inhibition of JAK2 V617F constitutive signaling from cytokine-stimulated signaling. 120 Similarly, inhibition of signaling by MPL/TPOR W515 or S505N mutants would require detailed structures of such mutated receptors that activate wildtype JAK2. A molecule specifically blocking cytosolic tyrosine Y626 of MPL/TPOR may be able to prevent the MF-inducing effects of MPL mutants, 153 but such phosphotyrosine blocking molecules are very difficult to obtain. A more global inhibitor of MPL/TPOR signaling may also be useful in certain cases of MPNs that progress to MF because of excessive MPL/TPOR signaling. However, inhibition of MPL/TPOR signaling in hematopoietic stem cells might lead to a reduction of hematopoietic stem cell quiescence and reservoir. [213] [214] [215] Whether the conformation of receptor-JAK complexes differ when the receptor or JAK are mutated remains to be established, but if this were the case, small molecules or peptides that would disrupt JAK2 V617F binding to cytokine receptors would prove useful (Figure 2) .
Apart from directly targeting JAK2 and MPL/TPOR, recently it was shown that preventing the association of JAK2 mutants with HSP90 leads to JAK2 degradation via ubiquitination. 119 Inhibitors of histone deacetylase 6, which is involved in deacetylation of HSP90, are attractive because acetylated HSP90 can no longer associate with JAK2. Givinostat, a pan-histone deacetylase inhibitor, induced a hematological response in most patients with PV and some patients with MF in a recent phase II clinical trial. 216 This introduces the concept of specifically targeting mutant JAKs for degradation, especially in the case of mutants of JAK2 or JAK2 V617F that are resistant to the inhibitory effects of JAK2 inhibitors. Such resistant mutants have been isolated in several experimental systems, either as spontaneous mutants in a cytokine autonomous selection model, in which JAK1-and JAK2-resistant mutants were identified, 217 or after random mutagenesis. 218, 219 None of the resistant mutants have yet been detected in patients. More recently, new JAK2 inhibitors targeting the degradation of the molecule have been developed 219 and may prove more promising for future therapy than the ATP competitive kinase inhibitors. HSP90 inhibitors are extremely efficient in murine models of MPNs including those driven with JAK2 inhibitor-resistant mutants. 119, 219 In principle, inhibitors of the downstream pathways emanating from JAK2 may be useful in the treatment of MPNs, provided that progenitors, that is, erythroid in PV or megakaryocytic in ET/PMF, are addicted to certain pathways in contrast to normal progenitors. Along these lines, inhibitors of STAT5, STAT3, MAP-kinase, PI3K, AKT and mTOR exist, and at least in cell lines and primary cells, mTOR inhibitors have proven useful. 220 It is possible that the combination of JAK2 inhibitors with inhibitors of downstream effectors including BCL2/BCL-XL (ABT-737) might be more effective. 221 Furthermore, a promising approach may be represented by the combination with epigenetic therapy as several major epigenetic regulators have been found to be mutated in MPNs; 222 JAK2 may induce epigenetic regulation; 116 and constitutive STAT5 signaling might have different target genes than the cytokine-induced STAT5 protein. 205 JAK inhibitors and such combined therapeutic strategies might be extended in the future to subsets of ALL with dysregulation of the JAK/STAT signaling and eventually to therapy-refractory Hodgkin lymphoma.
Certainly, it may be important to directly target STAT5 and STAT3, as their activation is involved in most hematological malignancies. Recently, it was shown that a molecule already developed, pimozide, was capable of inhibiting STAT5 activation in BCR-ABL cell lines. 223 Furthermore, the recent specific involvement of STAT1 in ET and not in PV 86 suggests that STAT1 inhibitors might limit thrombocytosis in certain situations. On the other hand, inhibition of these pathways is likely to exert secondary effects that might limit their use.
CONCLUSION
Numerous genetic alterations involving the JAK/STAT pathway, including JAK1, JAK2 and JAK3, have been discovered in hematological malignancies these last years. As in MPNs, they can drive the disease. JAK inhibitors have been developed with some clinical results, but they were moderate in comparison to the expectancies. A future task will be to develop new molecules or therapeutic strategies targeting more specifically the mutated forms of JAKs; a major challenge will be the development of molecules directly targeting the STAT proteins.
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